Stevanato Group (NYSE:STVN - Get Free Report) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.550-0.600 for the period, compared to the consensus earnings per share estimate of 0.670. The company issued revenue guidance of $1.2 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion. Stevanato Group also updated its FY24 guidance to EUR0.51-0.55 EPS.
Stevanato Group Price Performance
Shares of NYSE STVN traded down €5.81 ($6.25) during mid-day trading on Thursday, reaching €21.10 ($22.69). 4,692,200 shares of the company traded hands, compared to its average volume of 390,698. Stevanato Group has a fifty-two week low of €20.01 ($21.52) and a fifty-two week high of €36.30 ($39.03). The company has a debt-to-equity ratio of 0.23, a current ratio of 1.50 and a quick ratio of 1.06. The firm has a market cap of $6.24 billion, a PE ratio of 36.05, a price-to-earnings-growth ratio of 2.92 and a beta of 0.76. The stock has a fifty day simple moving average of €29.36 and a 200-day simple moving average of €29.04.
Stevanato Group (NYSE:STVN - Get Free Report) last posted its quarterly earnings results on Thursday, March 7th. The company reported €0.18 ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of €0.19 ($0.20) by (€0.01) (($0.01)). The business had revenue of €320.60 million during the quarter, compared to analyst estimates of €326.85 million. Stevanato Group had a return on equity of 14.31% and a net margin of 13.43%. The company's quarterly revenue was up 9.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.19 EPS. Equities research analysts anticipate that Stevanato Group will post 0.67 EPS for the current fiscal year.
Analyst Ratings Changes
STVN has been the topic of several recent research reports. BNP Paribas started coverage on shares of Stevanato Group in a research report on Monday, April 22nd. They issued an outperform rating on the stock. Morgan Stanley reaffirmed an equal weight rating and issued a $30.00 price objective on shares of Stevanato Group in a research note on Monday, April 22nd. Finally, Stephens reaffirmed an overweight rating and issued a $38.00 price objective on shares of Stevanato Group in a research note on Monday, March 25th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus price target of €34.29 ($36.87).
View Our Latest Report on Stevanato Group
About Stevanato Group
(
Get Free Report)
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
Further Reading
Before you consider Stevanato Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stevanato Group wasn't on the list.
While Stevanato Group currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
